Category - Developments

Developments

Titan posts positive results in first studies of TP-2021 implant in chronic pruritus

Titan Pharmaceuticals (NASDAQ:TTNP) reported that an in vivo study of its ProNeura-based human kappa-opioid receptor agonist, TP-2021, implant in an established itch-induced mouse model has demonstrated the...

June 23, 2021

Developments

CymaBay presents positive PBC data at the International Liver Congress

CymaBay Therapeutics (NASDAQ:CBAY) announced positive data at The International Liver Congress from its previously completed Phase 2 study and the ENHANCE Phase 3 study of seladelpar in patients with primary biliary...

June 21, 2021

Developments

Profound’s TULSA-PRO posts better safety, equal efficacy in real-world analysis of prostate cancer partial ablation, BPH

A peer-reviewed paper authored by clinicians and researchers from Germany’s ALTA Klinik and the University Hospital, LMU Munich, and published in Urologic Oncology illustrates that Profound Medical’s...

June 21, 2021

Developments

atai Life Sciences prices $225-million IPO

atai Life Sciences (NASDAQ:ATAI) priced an initial public offering of 15 million common shares at $15 each for gross proceeds of $225-million. In its first day of trading on June 18, the stock jumped $4.45, or 29%, to...

June 18, 2021

Developments

Versant, RA Capital launch LENZ Therapeutics in $47-million series A

A $47-million series A financing from Versant Ventures and RA Capital Management launched LENZ Therapeutics, with a lead late-stage clinical program for presbyopia. Proceeds from the financing will be used to progress...

June 17, 2021

Developments

Clearside Biomedical posts positive safety results in Phase 1/2a wet AMD study

Clearside Biomedical (NASDAQ:CLSD) reported positive safety results from Cohort 1 of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX, an axitinib injectable suspension, which is administered by suprachoroidal...

June 15, 2021

Developments

Lucid Psycheceuticals in pact with UHN to develop neurodegenerative therapeutics

Lucid Psycheceuticals inked a world-wide license agreement with Toronto’s University Health Network (UHN), Canada’s top research hospital, granting Lucid exclusive rights to novel compounds for therapeutic applications...

June 14, 2021

Developments

Hepion Pharmaceuticals to be added to the Russell Microcap Index

Hepion Pharmaceuticals (NASDAQ:HEPA) is set to join the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28. Membership in the...

June 9, 2021

Developments

Lancet article discusses benefits of PharmaJet Tropis ID needle-free delivery

A systematic review and meta-analysis published in the April 30, 2021 issue of The Lancet strengthens evidence that fractional dose delivery is a viable alternative to full dose inactivated polio vaccine (IPV) and...

June 3, 2021

Developments

Lineage reports additional cases of retinal tissue restoration in dry AMD with OpRegen

Lineage Cell Therapeutics (NASDAQ, TASE:LCTX) reported that restoration of retinal tissue was observed in two additional patients enrolled in the company’s Phase 1/2a study of its lead product candidate, OpRegen. ...

June 1, 2021

Category - Developments

Subscribe